Alizee Viandier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alizee Viandier has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Bjorn L. Millard
Residual Dynamics, Camano Island, Washington
51 shared publications - Bruno Daubeuf
Light Chain Bioscience - Novimmune S.A, Plan-Les-Ouates, Geneva, Switzerland
51 shared publications - Cecile Raymond
Light Chain Bioscience – Novimmune SA, Geneva, Switzerland
51 shared publications - Emily A. Pace
Residual Dynamics, Camano Island, Washington
51 shared publications - Franck Gueneau
Light Chain Bioscience – Novimmune SA, Geneva, Switzerland
51 shared publications - Giovanni Magistrelli
Light Chain Bioscience – Novimmune SA, Geneva, Switzerland
51 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S07 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
Fig. S7: The anti-CD28 arm AI3 is CD28 specific and does not cross-react with CTLA-4.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S07 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
Fig. S7: The anti-CD28 arm AI3 is CD28 specific and does not cross-react with CTLA-4.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S03 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
Table S3: Epitope and paratope residues as determined in the two independent AI3:CD28 complexes
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S03 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
Table S3: Epitope and paratope residues as determined in the two independent AI3:CD28 complexes
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S05 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
Fig. S5. Model calibration to NHP PK data
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S05 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
Fig. S5. Model calibration to NHP PK data
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S04 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
Table S4: Primary antibodies used for TME and LN ex vivo analysis by flow cytometry
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S04 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
Table S4: Primary antibodies used for TME and LN ex vivo analysis by flow cytometry
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S01 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
Table S1: Cell lines used in this study and related information
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S01 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
Table S1: Cell lines used in this study and related information
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S06 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
Table S6: Parameters for the 2-compartment NHP model
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S06 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
Table S6: Parameters for the 2-compartment NHP model
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S13 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
Fig. S13: NI-3201 synergized with a TCE enhancing T cell activation and the proliferative potential of T cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S13 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
Fig. S13: NI-3201 synergized with a TCE enhancing T cell activation and the proliferative potential of T cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S09 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
Fig. S9: NI-3201 enhanced T cell activation of PD-1 blockade.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S09 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
Fig. S9: NI-3201 enhanced T cell activation of PD-1 blockade.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S08 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
Fig. S8: The anti-CD28 arm AI3 is not a superagonist, not even in the context of the PD-L1xCD28 bsAb NI 3201.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S08 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
Fig. S8: The anti-CD28 arm AI3 is not a superagonist, not even in the context of the PD-L1xCD28 bsAb NI 3201.